clinical trial · NCT05407675
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb·phase2·completed·n = 68
Advanced Solid TumorsBMS-986408NivolumabIpilimumabPlatinum-doublet chemotherapyRabeprazole
brief summary
The primary purpose of this study is to characterize the safety profile of BMS-986408 as monotherapy and in combination with nivolumab or nivolumab and ipilimumab to establish the maximum tolerated dose (MTD). The Recommended Phase 2 Dose (RP2D) that optimizes the pharmacokinetic/pharmacodynamic (PK/PD) relationship of BMS-986408 will also be determined.
started
Aug 2, 2022
primary completion
Aug 22, 2024
completion
Jul 24, 2025
last updated
Aug 13, 2026
official title
A Phase 1/2 Study of BMS-986408 Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol